summary
Introduced
04/28/2021
04/28/2021
In Committee
07/29/2021
07/29/2021
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
AI Summary
This bill, the Affordable Prescriptions for Patients Act of 2021, amends the Federal Trade Commission Act to prohibit "product hopping" - a practice where drug manufacturers make minor changes to their products to prevent or delay generic or biosimilar competition. The bill defines "product hopping" and establishes that it is an unfair method of competition, with certain exceptions. The bill also limits the number of patents a reference product sponsor can assert against a biosimilar applicant in patent litigation. The amendments in this bill aim to promote competition and access to more affordable prescription drugs.
Committee Categories
Justice
Sponsors (17)
John Cornyn (R)*,
Richard Blumenthal (D),
Cory Booker (D),
Mike Braun (R),
Ted Cruz (R),
Dick Durbin (D),
Joni Ernst (R),
Chuck Grassley (R),
Josh Hawley (R),
Mark Kelly (D),
Angus King (I),
Amy Klobuchar (D),
Patrick Leahy (D),
Patty Murray (D),
Jon Ossoff (D),
Gary Peters (D),
Tina Smith (D),
Last Action
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably. (on 07/29/2021)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/senate-bill/1435/all-info |
| BillText | https://www.congress.gov/117/bills/s1435/BILLS-117s1435is.pdf |
| Bill | https://www.congress.gov/117/bills/s1435/BILLS-117s1435is.pdf.pdf |
Loading...